Skip to content
10-K

Annual Report

BridgeBio Oncology Therapeutics, Inc. BBOT

0001213900-25-022387

← back to feed
Filed
Mar 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Current Liabilities FY 2024 · Dec 31, 2023 $396.46K
Total Liabilities FY 2024 · Dec 31, 2023 $396.46K
Total Assets FY 2024 · Dec 31, 2023 $332.89K
Sga Expense FY 2024 · Dec 31, 2023 $41.69K
Net Income FY 2024 · Dec 31, 2023 −$41.69K
Operating Income FY 2024 · Dec 31, 2023 −$41.69K
Stockholders Equity FY 2024 · Dec 31, 2022 −$21.88K